Aurora Board Unanimously Rejects Curaleaf's Hostile Bid, Citing Inadequate Valuation and Regulatory Deficiencies
ACB sits 57% above its 52-week low of $2.56.
Summary
Aurora's board unanimously recommends rejecting Curaleaf's hostile bid, citing a fairness opinion that values Aurora at US$7.03 per share versus the US$4.00 offer, and revealing procedural defects in the bid. Aurora also urges shareholders who have tendered to withdraw their shares, highlighting Aurora's $149M cash versus Curaleaf's $1B debt and the bid's use of Aurora's own cash.
Updated with an SEC 6-K filing · What changed
Updates
· SEC 6-K — Aurora's 6-K attaches the news release urging shareholders to reject Curaleaf's bid, highlighting $149M cash vs Curaleaf's $1B debt and warning the bid would use Aurora's own cash to fix Curaleaf's balance sheet.
- Withdrawal Recommendation — Aurora's Board unanimously recommends shareholders who have tendered withdraw their shares, and directs them to contact their broker or Kingsdale Advisors at 1-800-749-9052 for assistance.
- Shareholder Risks — Shareholders would receive Curaleaf shares that may be harder to trade and could fluctuate in value, exposing them to Curaleaf's share price volatility, high-cost debt, tax uncertainties, regulatory risks, weak governance, limited liquidity, and lack of a U.S. national securities exchange listing.
- Valuation Concerns — A TD Securities analyst stated the bid undervalues Aurora, and Aurora believes Curaleaf's premium calculation makes the bid look better than the value shareholders would actually receive.
- Information Resource — Aurora directs shareholders to visit www.ProtectAurora.com for information about the hostile bid.
All 9 details
- Aurora's Board unanimously recommends that any Aurora shareholders who have tendered their shares to the Hostile Bid WITHDRAW those shares.
- Aurora directs shareholders to visit www.ProtectAurora.com for information about the hostile bid.
- Aurora shareholders would receive Curaleaf shares that may be harder to trade and could fluctuate in value before and after the bid closes.
- Shareholders would be exposed to Curaleaf's share price volatility, high-cost debt, tax uncertainties, regulatory risks, weak governance structure, limited liquidity and lack of a U.S. national securities exchange listing for Curaleaf shares.
- Shareholders who have already tendered their shares and wish to withdraw them should contact their broker or Kingsdale Advisors promptly for assistance.
- Kingsdale Advisors is Aurora's strategic advisor and information agent, with toll-free number 1-800-749-9052, call or text 416-623-4172, and email contactus@kingsdaleadvisors.com.
- TD Securities Inc. analyst stated bid undervalues Aurora, citing medical cannabis leadership, balance sheet flexibility, international expertise, long-term growth potential.
- Aurora believes Curaleaf's stated premium calculation makes the hostile bid look better than value shareholders would actually receive.
- Curaleaf's messaging focuses on headline premiums not reflecting Aurora's cash value or future growth opportunities.
Key Events · M&A and Partnerships · ACB
-
New · · SEC 6-K
Aurora Highlights Cash Position Versus Curaleaf's Debt
Aurora's news release highlights $149M cash versus Curaleaf's $1B debt and warns the bid would use Aurora's own cash to fix Curaleaf's balance sheet.
-
New · · SEC 6-K
Aurora Directs Shareholders to ProtectAurora.com
Aurora directs shareholders to visit www.ProtectAurora.com for information about the hostile bid.
-
New · · SEC 6-K
Aurora Warns of Curaleaf Share Risks
Aurora shareholders would receive Curaleaf shares that may be harder to trade and could fluctuate in value before and after the bid closes. Shareholders would be exposed to Curaleaf's share price volatility, high-cost debt, tax uncertainties, regulatory risks, weak governance structure, limited liquidity and lack of a U.S. national securities exchange listing for Curaleaf shares.
-
New · · SEC 6-K
Withdrawal Assistance Provided
Shareholders who have already tendered their shares and wish to withdraw them should contact their broker or Kingsdale Advisors promptly for assistance. Kingsdale Advisors is Aurora's strategic advisor and information agent, with toll-free number 1-800-749-9052, call or text 416-623-4172, and email contactus@kingsdaleadvisors.com.
-
New · · SEC 6-K
TD Securities Analyst Says Bid Undervalues Aurora
TD Securities Inc. analyst stated bid undervalues Aurora, citing medical cannabis leadership, balance sheet flexibility, international expertise, long-term growth potential.
-
New · · SEC 6-K
Aurora Challenges Curaleaf's Premium Calculation
Aurora believes Curaleaf's stated premium calculation makes the hostile bid look better than value shareholders would actually receive. Curaleaf's messaging focuses on headline premiums not reflecting Aurora's cash value or future growth opportunities.
-
Updated · · SEC 6-K
Board Unanimously Rejects Hostile Bid and Urges Withdrawal
Aurora's Board, on the unanimous recommendation of its Special Committee, formally recommends shareholders REJECT Curaleaf's US$4.00 per share offer and NOT TENDER their shares. The Board also unanimously recommends that any Aurora shareholders who have tendered their shares to the Hostile Bid WITHDRAW those shares.
-
Fairness Opinion Deems Offer Inadequate
Fort Capital Partners delivered a written opinion dated September 1, 2026, concluding the consideration is inadequate from a financial point of view. The bid implies 0.8x CY2026E revenue versus a 1.8x precedent transaction average, implying US$7.03 per share fair value.
-
Procedural Deficiencies Identified
The Circular states Curaleaf's bid period is truncated below the 105-day minimum required by Canadian securities laws and was not properly commenced in Quebec due to missing French-language advertisement.
-
U.S. Shareholders Face Forced Cash Sales
Individual Aurora shareholders in 29 U.S. states, districts, and territories would not receive Curaleaf shares but instead net cash proceeds from forced sales, subject to brokerage commissions, expenses, and withholding.
Analysis · ACB · Life Sciences
Aurora's Board of Directors has formally and unanimously recommended that shareholders reject Curaleaf's unsolicited takeover bid, backed by a fairness opinion from Fort Capital Partners concluding the US$4.00 per share offer is financially inadequate. The Directors' Circular reveals that the bid implies a 0.8x revenue multiple versus a 1.8x average for recent Canadian cannabis transactions, suggesting a fair value of US$7.03 per share — 76% above the offer. The filing also discloses that Curaleaf's bid is procedurally defective: it fails to meet the 105-day minimum period under Canadian securities laws and was not properly commenced in Quebec. Additionally, shareholders in 29 U.S. states would not receive Curaleaf shares but instead forced cash sales with deductions. Aurora's news release urges shareholders who have tendered to withdraw their shares, highlighting Aurora's $149M cash versus Curaleaf's $1B debt and warning the bid would use Aurora's own cash to fix Curaleaf's balance sheet. This is the first formal board response with full valuation analysis and legal objections, materially escalating the takeover defense.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 44.6% of the 296 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACB was trading at $4.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $262.6M. The 52-week trading range was $2.56 to $6.67. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.